Showing results (41-50 of 54) with videos related to
Sort By:
Pageof 6
British Journal of Haematology|April 3, 2015
Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantationMathew Weinstock, Yosra Aljawai, Elizabeth A Morgan, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|January 24, 2021
Increased thickness of lumbar spine ligamentum flavum in wild-type transthyretin amyloidosisKeith M George, Nicholas S Hernandez, Jeffrey Breton, et al.Clinical Lymphoma, Myeloma & Leukemia|August 15, 2018
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17pSandy W Wong, Ute Hegenbart, Giovanni Palladini, et al.British Journal of Haematology|June 3, 2015
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinationsCindy Varga, Wanling Xie, Jacob Laubach, et al.Clinical Neurology and Neurosurgery|May 31, 2021
Lumbar ligamentum flavum burden: Evaluating the role of ATTRwt amyloid deposition in ligamentum flavum thickness at all lumbar levelsKeith M George, Nicholas S Hernandez, Jeffrey Breton, et al.Clinical Lymphoma, Myeloma & Leukemia|May 1, 2023
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First RelapseManisha Bhutani, David M Foureau, Myra Robinson, et al.Journal of the American Geriatrics Society|August 5, 2022
Analysis of lumbar spine stenosis specimens for identification of amyloidMathew S Maurer, Dia Smiley, Eli Simsolo, et al.Journal of Clinical Medicine|June 26, 2025
Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal GammopathiesPing Zhou, Mahesh M Mansukhani, Raymond Yeh, et al.Blood Advances|November 22, 2024
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myelomaManisha Bhutani, Myra Robinson, David Foureau, et al.Blood Advances|February 20, 2026
Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myelomaShebli Atrash, James Symanowski, Myra Robinson, et al.Pageof 6